Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2014

Open Access 01-02-2014 | Research

High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis

Authors: Edward Clark, Amber O Molnar, Olivier Joannes-Boyau, Patrick M Honoré, Lindsey Sikora, Sean M Bagshaw

Published in: Critical Care | Issue 1/2014

Login to get access

Abstract

Introduction

High-volume hemofiltration (HVHF) is an attractive therapy for the treatment of septic acute kidney injury (AKI). Small experimental and uncontrolled studies have suggested hemodynamic and survival benefits at higher doses of HVHF than those used for the high-intensity arms of the RENAL and ATN studies. Our aim was to evaluate the effects of high-volume hemofiltration (HVHF) compared with standard-volume hemofiltration (SVHF) for septic AKI.

Methods

A systematic review and meta-analysis of publications between 1966 and 2013 was performed. The review was limited to randomized-controlled trials that compared HVHF (effluent rate greater than 50 ml/kg per hour) versus SVHF in the treatment of sepsis and septic shock. The primary outcome assessed was 28-day mortality. Other outcomes assessed were recovery of kidney function, lengths of ICU and hospital stays, vasopressor dose reduction, and adverse events.

Results

Four trials, including 470 total participants, were included. Pooled analysis for 28-day mortality did not show any meaningful difference between HVHF compared with SVHF (OR, 0.76; 95% CI, 0.45 to 1.29). No included studies reported statistically significant differences between groups for any of the secondary outcomes. Adverse events, including hypophosphatemia and hypokalemia, were more commonly observed in HVHF-treated patients, although reporting was inconsistent across studies.

Conclusions

Insufficient evidence exists of a therapeutic benefit for routine use of HVHF for septic AKI, other than on an experimental basis. Given the logistic challenges related to patient recruitment along with an incomplete understanding of the biologic mechanisms by which HVHF may modify outcomes, further trials should focus on alternative extracorporeal therapies as an adjuvant therapy for septic AKI rather than HVHF.
Appendix
Available only for authorised users
Literature
1.
Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348: 1546-1554. 10.1056/NEJMoa022139CrossRefPubMed
2.
Di Carlo JV, Alexander SR: Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005, 28: 777-786.PubMed
3.
Honore PM, Matson JR: Extracorporeal removal for sepsis: acting at the tissue level–the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004, 32: 896-897. 10.1097/01.CCM.0000115262.31804.46CrossRefPubMed
4.
Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003, 27: 792-801. 10.1046/j.1525-1594.2003.07289.xCrossRefPubMed
5.
Atan R, Crosbie D, Bellomo R: Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif 2012, 33: 88-100. 10.1159/000333845CrossRefPubMed
6.
7.
Cariou A, Vinsonneau C, Dhainaut JF: Adjunctive therapies in sepsis: an evidence-based review. Crit Care Med 2004, 32: S562-S570. 10.1097/01.CCM.0000142910.01076.A5CrossRefPubMed
8.
Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al.: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009, 361: 1627-1638.CrossRefPubMed
9.
Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al.: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008, 359: 7-20.CrossRefPubMed
10.
Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK: High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med 2010, 38: 1360-1369.PubMed
11.
Jun M, Heerspink HJ, Ninomiya T, Gallagher M, Bellomo R, Myburgh J, et al.: Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2010, 5: 956-963. 10.2215/CJN.09111209PubMedCentralCrossRefPubMed
12.
Kellum JA, Ronco C: Dialysis: results of renal–what is the optimal CRRT target dose? Nat Rev Nephrol 2010, 6: 191-192.CrossRefPubMed
13.
Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C: The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002, 62: 1855-1863.CrossRefPubMed
14.
Grootendorst AF, van Bommel EF, van der Hoven B, van Leengoed LA, van Osta AL: High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 1992, 18: 235-240. 10.1007/BF01709839CrossRefPubMed
15.
Rogiers P, Zhang H, Smail N, Pauwels D, Vincent JL: Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 1999, 27: 1848-1855. 10.1097/00003246-199909000-00024CrossRefPubMed
16.
Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, et al.: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000, 356: 26-30. 10.1016/S0140-6736(00)02430-2CrossRefPubMed
17.
Honore PM, Jacobs R, Boer W, Joannes-Boyau O, De Regt J, De Waele E, et al.: New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 2012, 33: 44-51. 10.1159/000333837CrossRefPubMed
18.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339: b2535. 10.1136/bmj.b2535PubMedCentralCrossRefPubMed
19.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4CrossRefPubMed
20.
Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P: High-volume haemofiltration in human septic shock. Intensive Care Med 2001, 27: 978-986. 10.1007/s001340100963CrossRefPubMed
21.
Peng Z, Pai P, Han-Min W, Jun Z, Hong-Bao L, Rong L, et al.: Evaluation of the effects of pulse high-volume hemofiltration in patients with severe sepsis: a preliminary study. Int J Artif Organs 2010, 33: 505-511.PubMed
22.
Schrover I, Dalhuisen A, Steenbergen H, Hofhuis J, Rommes JH, Spronk PE: Observations during high and low volume hemofiltration in septic shock patients (abstract 0153). Intensive Care Med 2009, 35: S43.
23.
Borthwick EM, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B: High-volume haemofiltration for sepsis. Cochrane Database Syst Rev 2013., 1: CD008075
24.
Ghani RA, Zainudin S, Ctkong N, Rahman AF, Wafa SR, Mohamad M, et al.: Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton) 2006, 11: 386-393. 10.1111/j.1440-1797.2006.00600.xCrossRef
25.
Boussekey N, Chiche A, Faure K, Devos P, Guery B, d’Escrivan T, et al.: A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008, 34: 1646-1653. 10.1007/s00134-008-1127-3CrossRefPubMed
26.
Joannes-Boyau O, Honore PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al.: High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013, 39: 1535-1546. 10.1007/s00134-013-2967-zCrossRefPubMed
27.
Sanchez C, Corbalan P, Rodriguez F, Sanchez A, Palominos S: High volume hemofiltration vs. very high volume hemofiltration: effects on hemodynamics in patients with severe sepsis: a nursing approach [Abstract]. Intensive Care Med 2010, 36: S193. 10.1007/s00134-009-1710-2CrossRef
28.
Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen J: Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transplant 2012, 27: 967-973. 10.1093/ndt/gfr486CrossRefPubMed
29.
Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al.: Newly designed CRRT membranes for sepsis and SIRS: a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J 2013, 59: 99-106. 10.1097/MAT.0b013e3182816a75CrossRefPubMed
30.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9CrossRefPubMed
31.
Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, et al.: Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008, 61: 436-441.CrossRefPubMed
32.
Demirjian S, Teo BW, Guzman JA, Heyka RJ, Paganini EP, Fissell WH, et al.: Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant 2011, 26: 3508-3514. 10.1093/ndt/gfr075CrossRefPubMed
33.
Schiffl H, Lang SM: Severe acute hypophosphatemia during renal replacement therapy adversely affects outcome of critically ill patients with acute kidney injury. Int Urol Nephrol 2013, 45: 191-197. 10.1007/s11255-011-0112-xCrossRefPubMed
34.
Basso F, Ricci Z, Cruz D, Ronco C: International survey on the management of acute kidney injury in critically ill patients: year 2007. Blood Purif 2010, 30: 214-220. 10.1159/000320126CrossRefPubMed
35.
Karvellas CJ, Farhat MR, Sajjad I, Mogensen SS, Leung AA, Wald R, et al.: A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care 2011, 15: R72. 10.1186/cc10061PubMedCentralCrossRefPubMed
36.
Piccinni P, Dan M, Barbacini S, Carraro R, Lieta E, Marafon S, et al.: Early isovolaemichaemofiltration in oliguric patients with septic shock. Intensive Care Med 2006, 32: 80-86. 10.1007/s00134-005-2815-xCrossRefPubMed
37.
Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, et al.: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000, 28: 3581-3587. 10.1097/00003246-200011000-00001CrossRefPubMed
38.
Joannes-Boyau O, Rapaport S, Bazin R, Fleureau C, Janvier G: Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J 2004, 50: 102-109. 10.1097/01.MAT.0000104846.27116.EACrossRefPubMed
39.
Ratanarat R, Brendolan A, Piccinni P, Dan M, Salvatori G, Ricci Z, et al.: Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 2005, 9: R294-R302. 10.1186/cc3529PubMedCentralCrossRefPubMed
40.
Bellomo R, Kellum JA, Gandhi CR, Pinsky MR, Ondulik B: The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000, 161: 1429-1436. 10.1164/ajrccm.161.5.9809127CrossRefPubMed
41.
Lee PA, Matson JR, Pryor RW, Hinshaw LB: Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus -induced septicemia in immature swine. Crit Care Med 1993, 21: 914-924. 10.1097/00003246-199306000-00022CrossRefPubMed
42.
Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996, 125: 605-613. 10.7326/0003-4819-125-7-199610010-00011CrossRefPubMed
43.
Brower RG, Fessler HE: Mechanical ventilation in acute lung injury and acute respiratory distress syndrome. Clin Chest Med 2000, 21: 491-510. viii 10.1016/S0272-5231(05)70161-1CrossRefPubMed
44.
Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care: Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340: 409-417. 10.1056/NEJM199902113400601CrossRefPubMed
45.
Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004, 32: 21-30. 10.1097/01.CCM.0000105581.01815.C6CrossRefPubMed
46.
Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, et al.: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999, 341: 785-792. 10.1056/NEJM199909093411102CrossRefPubMed
47.
Honore PM, Joannes-Boyau O: High volume hemofiltration (HVHF) in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research. Int J Artif Organs 2004, 27: 1077-1082.PubMed
48.
Bellomo R, Lipcsey M, Calzavacca P, Haase M, Haase-Fielitz A, Licari E, et al.: Early acid–base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Med 2013, 39: 429-436. 10.1007/s00134-012-2800-0CrossRefPubMed
49.
Leandro G: How to interpret a randomized controlled study stopped early. Intensive Care Med 2013, 39: 1642-1643. 10.1007/s00134-013-3000-2CrossRefPubMed
Metadata
Title
High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis
Authors
Edward Clark
Amber O Molnar
Olivier Joannes-Boyau
Patrick M Honoré
Lindsey Sikora
Sean M Bagshaw
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13184

Other articles of this Issue 1/2014

Critical Care 1/2014 Go to the issue

Journal club critique

Should β-blockers be used in septic shock?

Review

Heart–kidney crosstalk and role of humoral signaling in critical illness

Research

Feasibility and reliability of an automated controller of inspired oxygen concentration during mechanical ventilation

Research

Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Letter

Colistin dosing for treatment of multidrug-resistant Pseudomonasin critically ill patients - please, be adequate!

Commentary

Time to look beyond one-year mortality in critically ill hematological patients?